Stayble Therapeutics clinical phase IIb study with STA363 takes no break in the summer heat. Approximately 90% of the patients have now completed their 12-month follow-up, which shows that the company has good opportunities to present top-line data during the fourth quarter of this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2375 SEK | -0.63% | -13.79% | -21.62% |
1st Jan change | Capi. | |
---|---|---|
-21.62% | 696K | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Therapeutics Phase IIb Study Nears the Final Line